Recent advances in targeted immunotherapy for canine atopic dermatitis including Janus kinase inhibitors and monoclonal antibodies have transformed welfare outcomes for many affected dogs.
The development of JAK inhibitors and IL-31 monoclonal antibodies has dramatically improved welfare outcomes for dogs with atopic dermatitis by providing rapid, effective itch relief with significantly lower adverse effect burden than traditional immunosuppressants. The speed of oclacitinib action provides particularly rapid welfare relief for severely pruritic dogs. Long-term management with these targeted therapies maintains itch control with a favourable safety profile, enabling sustained welfare improvement over years. The main limitation to welfare impact is cost: many owners cannot afford monthly or ongoing treatment, leaving some dogs inadequately managed for economic rather than medical reasons.